CS
OACCU

Clear Street’s Oaktree Acquisition Corp III Life Sciences Unit OACCU Stock Holding History

Clear Street’s Portfolio OACCU Stock Details OACCU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$236K Hold
22,221
– – ﹤0.01% 531
2025
Q4 		$238K Buy
22,221
+1,888
+9% +$20.3K ﹤0.01% 439
2025
Q3 		$217K Sell
20,333
-487
-2% -$5.2K ﹤0.01% 345
2025
Q2 		$221K Buy
20,820
+19,588
+1,590% +$206K ﹤0.01% 209
2025
Q1 		$12.9K Buy
+1,232
New +$12.6K ﹤0.01% 345

Other funds holding OACCU

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Clear Street's OACCU Position: Q1 2026 in Review

Clear Street held its Oaktree Acquisition Corp III Life Sciences Unit (OACCU) position steady in Q1 2026 at 22,221 shares worth $236K. The position accounts for ﹤0.01% of the portfolio, ranked #531.

Clear Street first reported a position in OACCU in Q1 2025 and has held it in 5 quarters since. The position peaked at $238K in Q4 2025. 6 funds tracked by Wall St. Rank hold OACCU as of Q1 2026.

  • Clear Street held 22,221 shares of Oaktree Acquisition Corp III Life Sciences Unit worth $236K as of Q1 2026.
  • Clear Street left its Oaktree Acquisition Corp III Life Sciences Unit share count unchanged in Q1 2026.
  • Oaktree Acquisition Corp III Life Sciences Unit made up ﹤0.01% of Clear Street's portfolio in Q1 2026, its #531 holding.
  • Clear Street first reported a position in Oaktree Acquisition Corp III Life Sciences Unit in Q1 2025 and has held it in 5 quarters since.
  • Clear Street's Oaktree Acquisition Corp III Life Sciences Unit position peaked at $238K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Unit as of Q1 2026.

Based on Clear Street's 13F filing for Q1 2026, filed 15 May 2026.